Personalized Epigenetics
- 2nd Edition - July 17, 2024
- Editor: Trygve Tollefsbol
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 2 3 8 0 2 - 4
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 3 8 0 3 - 1
Personalized Epigenetics, Second Edition discusses the core translatability of epigenetics to health management of individuals who have unique variations in their epigeneti… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quotePersonalized Epigenetics, Second Edition discusses the core translatability of epigenetics to health management of individuals who have unique variations in their epigenetic signatures that can guide both disorder and disease prevention and therapy. Fully updated and revised, this new edition details inter-individual variability in the major epigenetic process in humans consisting of DNA methylation, histone modifications, noncoding RNA, and the diagnostic, prognostic, and therapeutic potential of the field. It also reviews the impact of the environment on epigenetic variations among individuals and the role of pharmacology and drug development in personalized epigenetics.
Most importantly, the text covers personalized epigenetics from a disease-oriented perspective, presenting chapters that provide advances in widespread disorders or diseases, including diabetes, cancer, autoimmune disorders, obesity, cardiovascular diseases, neurological disorders, and pain management.
- Includes new chapters on topics such as the limitations of personalized epigenetic variation comparisons; personalized epigenetics technologies; epigenetics of personalized nanomedicine; personalized epigenetic management of diabetes; epigenetics and chemoresistance; and personalized epigenetics and neurological disorders
- Covers key methodological processes that are important in personalized medicine
- Offers disease research case studies to provide in-depth discussion of examples of recent epigenetic research on a disease area
- Features topics such as forensic epigenetics, epigenetics of personalized toxicity, limitations of epigenetic variation comparisons, and nanomedicine and nutrigenomics as applied to personalized epigenetics
University researchers, health care professionals, graduate students and post graduates studying life sciences, genetic and/or human diseases, particularly the epigenetics-healthcare relationship as well as pharmaceutical and biotechnology companies interested in drug development
- Cover image
- Title page
- Table of Contents
- Front Matter
- Copyright
- Contributors
- Preface
- Section I: Introduction
- Chapter 1 Epigenetics of personalized medicine
- Abstract
- 1 Introduction
- 2 Epigenetic variations among individuals
- 3 Technologies for personalized epigenetics
- 4 Diagnostic and prognostic epigenetic approaches to personalized medicine
- 5 Environmental personalized epigenetics
- 6 Pharmacology and drug development of personalized epigenetics
- 7 Personalized epigenetics of obesity and diabetes
- 8 Personalized epigenetics of cancer
- 9 Personalized epigenetics of neurological disorders and diseases
- 10 Personalized epigenetics of other disorders and diseases
- 11 Personalized epigenetics of pain management
- 12 Challenges and future directions
- 13 Conclusion
- References
- Section II: Epigenetic variations among individuals
- Chapter 2 Personalized epigenetics: Analysis and interpretation of DNA methylation variation
- Abstract
- 1 Introduction
- 2 DNA methylation and demethylation mechanisms
- 3 Genetic and epigenetic variations
- 4 Allelic-specific DNA methylation
- 5 Blood cellular heterogeneity and methylation variation
- 6 Brain cellular heterogeneity and methylation variation
- 7 Stem cellular heterogeneity and methylation variation
- 8 Quantitative assessment of DNA methylation variation
- 9 Closing remarks
- References
- Chapter 3 Differences in histone modifications between individuals
- Abstract
- 1 Introduction
- 2 Chromatin structure and histone modifications
- 3 Analytical toolboxes for chromatin structure and histone modifications
- 4 Copy number variations, quantitative trait loci, and single-nucleotide polymorphisms influence histone modifications
- 5 The exposome; Different exposures induce differential modification of histones
- 6 The metabolome: Differential metabolism and its influence on differential modifications of histones
- 7 Interactive effects of the exposome and metabolome on histone modifications
- 8 Prospects for the analysis of histone modifications in humans
- 9 Conclusion
- References
- Chapter 4 Individual noncoding RNA variations: Their role in shaping and maintaining the epigenetic landscape
- Abstract
- 1 Introduction
- 2 Regulatory interactions between microRNAs and epigenetic machinery
- 3 MicroRNA-mediated regulation of epigenetic machinery
- 4 Epigenetic alterations and regulation of trinucleotide repeats in neurodegenerative diseases
- 5 Long noncoding RNAs guide the epigenetic machinery and interfere with other noncoding RNA functions to regulate gene expression
- 6 Conclusion
- References
- Section III: Technologies for personalized epigenetics
- Chapter 5 Epigenetics technologies for personalized medicine
- Abstract
- 1 Introduction
- 2 Higher-order chromosomal structure profiling platforms
- 3 CRISPR-based epigenetic modification
- 4 Epigenetics and personalized therapies
- 5 Epigenetic applications in personalized medicine
- 6 Current personalized medicines
- 7 Challenges and future directions
- References
- Chapter 6 Computational methods in epigenetics
- Abstract
- 1 Introduction
- 2 Before you begin
- 3 Key resources table
- 4 Step-by-step method details
- 5 Expected outcomes
- 6 Quantification and statistical analysis
- 7 Advantages
- 8 Limitations
- 9 Optimization and troubleshooting
- 10 Safety considerations and standards
- References
- Section IV: Diagnostic and prognostic epigenetic approaches to personalized medicine
- Chapter 7 Epigenetic biomarkers in personalized medicine
- Abstract
- 1 Introduction
- 2 Cancer
- 3 Noncancerous diseases
- 4 Concluding remarks
- References
- Chapter 8 Forensic epigenetics in the massively parallel sequencing era
- Abstract
- Acknowledgments
- 1 Introduction
- 2 Analytical approaches in forensic epigenetics
- 3 Fluid and tissue identification
- 4 Epigenetic age prediction
- 5 Monozygotic twins
- 6 Lifestyle
- 7 Pollution and location
- 8 Conclusion
- References
- Chapter 9 Epigenetics in personalized toxicity
- Abstract
- 1 Foreword
- 2 Introduction to personalized toxicity
- 3 Role of epigenetics in personalized toxicity
- 4 Epigenetic variations and adverse drug response
- 5 Epigenetic mechanisms underlying differential susceptibility to toxicity
- 6 Integration of epigenetic analysis in toxicology
- 7 Analytics beyond sequencing: Mass spectrometry in epigenetics
- 8 Conclusions and future perspectives
- References
- Section V: Environmental personalized epigenetics
- Chapter 10 Environmental contaminants and the epigenome
- Abstract
- 1 Introduction
- 2 Overview of epigenetic mechanisms and methods for assessment
- 3 Inorganic metals and the epigenome
- 4 Complex mixtures
- 5 Further considerations
- References
- Chapter 11 Nutriepigenomics: Paving the way for personalized nutrition
- Abstract
- 1 Introduction
- 2 Connection between chromatin structure and metabolic status
- 3 Evidence for dietary factors affecting epigenetic patterns
- 4 Epigenetic biomarkers—Novel tools to assess metabolic disorders and diet response
- 5 Conclusions and future perspectives
- References
- Section VI: Pharmacology and drug development of personalized epigenetics
- Chapter 12 Personalized pharmacoepigenomics
- Abstract
- 1 Introduction
- 2 Genome-wide epigenetic studies
- 3 Pharmacoepigenomics in relation to pharmacodynamics
- 4 Personalized pharmacoepigenomics in relation to pharmacodynamics
- 5 Pharmacoepigenomics in relation to pharmacokinetics
- 6 Personalized pharmacoepigenomics in relation to pharmacokinetics
- 7 Personalized pharmacoepigenomics in relation to adverse effects of drugs
- 8 Personalized pharmacoepigenomics in relation to pharmacometrics
- 9 Systems pharmacology and personalized pharmacoepigenomics
- 10 Conclusions
- 11 Future directions
- References
- Chapter 13 Personalized medicine and epigenetic drug development
- Abstract
- 1 Introduction
- 2 Epigenetics and drug discovery
- 3 Personalized medicine
- 4 Conclusions
- References
- Section VII: Personalized epigenetics of obesity and diabetes
- Chapter 14 Understanding interindividual epigenetic variation in obesity and its management
- Abstract
- 1 Introduction
- 2 Diet, epigenetic signatures, and obesity risk
- 3 Epigenetic biomarkers of weight loss after dietary interventions
- 4 Conclusions
- References
- Chapter 15 Personalized epigenetic management of diabetes
- Abstract
- 1 Epigenetic modifications in diabetes
- 2 Epigenetic alterations associated with adipogenesis and impaired glucose mechanisms
- 3 Epigenetic modification responsible for the pathogenesis of diabetes
- 4 Epigenetic modifications leading to diabetic comorbidities
- 5 Epigenetic signatures in identifying the risk of diabetes and its comorbidities
- 6 Knowledge gap in diabetes, guidelines, and medical practice
- 7 Role of epigenetic modifications in early diagnosis of diabetes
- 8 Epigenetic drugs in the prevention of diabetes
- 9 Epigenetic therapeutic opportunities
- 10 Conclusion and future perspective
- References
- Section VIII: Personalized epigenetics of cancer
- Chapter 16 Personalized epigenetics of DNA methylation in cancer
- Abstract
- 1 Introduction
- 2 The interplay between DNA methylation and cancer
- 3 Sequencing methodologies for DNA methylation profiling
- 4 Clinical applications of DNA methylation in cancer management
- 5 Limitations and drawbacks
- 6 Future perspectives and novel strategies
- References
- Chapter 17 Histone modification and personalized epigenomics in cancer
- Abstract
- 1 Posttranslational modifications overview
- 2 Histone proteins
- 3 History of PTM in histone proteins
- 4 The role of aberrant PTMs in the histone tail and their role in cancer
- 5 Histone PTM in personalized epigenetics
- 6 Signaling pathway changed by histone PTM in cancers
- 7 Discussion
- References
- Chapter 18 Epigenetic modification of miRNA in cancer
- Abstract
- Conflict of interest statement
- 1 Introduction
- 2 miRNA biogenesis and its dysregulation in cancer
- 3 Genetic and epigenetic changes in regulators of miRNA biogenesis
- 4 The role of miRNAs as diagnostic, prognostic, and predictive biomarkers for monitoring cancer therapy response
- 5 miRNA-based approach in anticancer treatment
- 6 Conclusions and future perspectives
- Case report: The efficacy of polylactic-co-glycolic acid-poly-l-histidine nanoparticles to deliver miR-34a mimic in lung adenocarcinoma both in vitro and in vivo
- References
- Chapter 19 Role of epigenetics in drug-resistance: A personalized approach to cancer therapy
- Abstract
- 1 Summary
- 2 Introduction
- 3 Drug resistance of cancer cells
- 4 Types of epigenetic changes
- 5 Epigenetic modifications in cancers
- 6 Drug resistance role of epigenetics
- 7 Personalized epigenetics in cancer therapy
- 8 Future perspective of personalized epigenetics in cancer therapy
- 9 Challenges of personalized epigenetics-based cancer therapy
- 10 Case study
- 11 Conclusion
- References
- Section IX: Personalized epigenetics of neurological disorders and diseases
- Chapter 20 Personalized epigenetics and neurological disorders
- Abstract
- 1 Introduction
- 2 Basic principles of epigenetic mechanism in the brain
- 3 Epigenetics: A connection between environmental signals and genome response during early life in neurological disorders
- 4 Genetic and epigenetic modifications involved in schizophrenia
- 5 Alterations in epigenome in schizophrenia
- 6 Altered DNA methylation in schizophrenia subjects
- 7 Regulating factors associated with DNA methylation in schizophrenia
- 8 Link between miRNA modifications in schizophrenia
- 9 Genome imprinting in schizophrenia
- 10 Importance of personalized epigenetics in schizophrenia
- 11 DNA methylation changes induced by treatment with schizophrenia-associated drugs
- 12 Challenges of personalized epigenetics in neurological disorders
- 13 Conclusion
- References
- Chapter 21 Personalized epigenetics of neurodegenerative diseases
- Abstract
- 1 Introduction
- 2 Neurodegenerative diseases
- 3 Conclusion
- References
- Section X: Personalized epigenetics of other disorders and diseases
- Chapter 22 Managing autoimmune disorders through personalized epigenetic approaches
- Abstract
- 1 Introduction
- 2 Evolution of the treatment of autoimmunity
- 3 Epigenetic basis for autoimmunity
- 4 Lessons from oncology
- 5 Personalized epigenetic therapy in autoimmune diseases
- 6 Specific epigenetic agents in autoimmunity
- 7 Environmental agents involved in autoimmunity that influence epigenetics
- 8 Big data and epigenetics
- 9 Discussion
- 10 Conclusions
- References
- Chapter 23 Advances in personalized epigenetics in infectious diseases
- Abstract
- 1 Introduction
- 2 Epigenetic modifications associated with malaria
- 3 Epigenetic modifications associated with TB
- 4 Epigenetic modifications associated with HIV
- 5 Epigenetic modifications associated with cryptococcal meningitis and schistosomiasis
- 6 Guidelines for personalized epigenetics in infectious diseases
- References
- Chapter 24 Personalized epigenetics of aging
- Abstract
- 1 Introduction
- 2 Epigenetic mechanisms in aging
- 3 Epigenetic variability and aging
- 4 Personalized epigenetic aging clocks
- 5 Epigenetic interventions for healthy aging
- 6 Concluding remarks and future directions
- Case study: Exploring the main determinants of epigenetic aging in early life
- References
- Section XI: Personalized epigenetics of pain management
- Chapter 25 Epigenetics and personalized pain management
- Abstract
- 1 Introduction
- 2 Pain basics: What you need to know
- 3 Epigenetics in individual differences of pain
- 4 Epigenetics in response to pain
- 5 Pharmacotherapy for personalized pain management in clinical practice
- 6 Potential pain therapy using clinically available drugs and their effects on epigenetics
- 7 Diseases and injuries causing chronic pain and their associations with epigenetics
- 8 Opioid-use disorder and epigenetics
- 9 Summary
- References
- Section XII: Challenges and future directions
- Chapter 26 Future challenges and prospects for personalized epigenetics
- Abstract
- 1 Introduction
- 2 Future research direction of personalized epigenetics
- 3 Prospects of personalized epigenetics
- 4 Challenges of personalized epigenetics
- 5 Epigenetic data vs genetic data in personalized medicine
- 6 Conclusions
- References
- Index
- No. of pages: 780
- Language: English
- Edition: 2
- Published: July 17, 2024
- Imprint: Academic Press
- Paperback ISBN: 9780443238024
- eBook ISBN: 9780443238031
TT
Trygve Tollefsbol
Dr. Tollefsbol is a Professor of Biology and a Senior Scientist in the Center for Aging, Comprehensive Cancer Center, Nutrition Obesity Research Center, and the Comprehensive Diabetes Center at the University of Alabama at Birmingham (UAB). He is Director of the UAB Cell Senescence Culture Facility which he established in 1999 and a Steering Committee Member of the UAB Center for Aging. Dr. Tollefsbol trained as a Postdoctoral Fellow and Assistant Research Professor with members of the National Academy of Science at Duke University and the University of North Carolina. He earned doctorates in molecular biology and osteopathic medicine from the University of North Texas Health Sciences Center and his bachelor’s degree in biology from the University of Houston. He has received prior funding from the NIA, NCI, NHLBI, NIMH and other federal institutes as well as the Glenn Foundation for Medical Research, Susan G. Komen for the Cure, the American Federation for Aging Research (AFAR), and the American Institute for Cancer Research (AICR) among many other sources.
Affiliations and expertise
Professor of Biology
Senior Scientist, Comprehensive Cancer Center
Senior Scientist, Comprehensive Center for Healthy Aging
Senior Scientist, Comprehensive Diabetes Center
Senior Scientist, Nutrition Obesity Research Center
Director, Cell Senescence Culture Facility
University of Alabama at Birmingham, AL, USARead Personalized Epigenetics on ScienceDirect